APG Asset Management N.V. Decreases Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• APG Asset Management N.V. reduced its stake in Teva Pharmaceutical Industries by 32.3%, owning 46,665 shares valued at $664,000 after selling 22,229 shares in the first quarter.
• Other institutional investors significantly increased their stakes in Teva, with Harel Insurance Investments raising their holdings by 197,885.2% during the same period.
• Teva Pharmaceutical reported earnings of $0.66 per share for the last quarter, exceeding expectations, but revenue was below estimates at $4.18 billion.

APG Asset Management N.V. lessened its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 32.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 46,665 shares of the company's stock after selling 22,229 shares during the quarter. APG Asset Management N.V.'s holdings in Teva Pharmaceutical Industries were worth $664,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Harel Insurance Investments & Financial Services Ltd. boosted its holdings in Teva Pharmaceutical Industries by 197,885.2% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 22,055,547 shares of the company's stock worth $338,989,000 after acquiring an additional 22,044,407 shares during the period. Duquesne Family Office LLC boosted its holdings in Teva Pharmaceutical Industries by 530.1% in the 4th quarter. Duquesne Family Office LLC now owns 8,997,400 shares of the company's stock worth $198,303,000 after acquiring an additional 7,569,450 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Teva Pharmaceutical Industries by 472.8% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 6,283,688 shares of the company's stock worth $96,078,000 after acquiring an additional 5,186,592 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Teva Pharmaceutical Industries by 416.0% in the 1st quarter. Assenagon Asset Management S.A. now owns 5,983,928 shares of the company's stock worth $91,973,000 after acquiring an additional 4,824,247 shares during the period. Finally, Nuveen LLC purchased a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $40,827,000. Hedge funds and other institutional investors own 54.05% of the company's stock.

Insider Activity at Teva Pharmaceutical Industries

In related news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Eric A. Hughes sold 52,742 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,001 shares of company stock valued at $996,958. Corporate insiders own 0.55% of the company's stock.

Teva Pharmaceutical Industries Stock Performance

TEVA stock opened at $18.18 on Wednesday. The company has a current ratio of 1.06, a quick ratio of 0.77 and a debt-to-equity ratio of 2.45. The firm has a market cap of $20.85 billion, a P/E ratio of -113.59, a P/E/G ratio of 1.07 and a beta of 0.62. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $22.80. The stock's 50 day simple moving average is $16.79 and its 200 day simple moving average is $16.29.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.The business's revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the company posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. As a group, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TEVA shares. Bank of America upped their price target on Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday, May 8th. UBS Group reduced their target price on Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. The Goldman Sachs Group began coverage on Teva Pharmaceutical Industries in a research note on Friday, June 6th. They set a "buy" rating and a $24.00 target price for the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Finally, Truist Financial began coverage on Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.